Key Highlights
- CareDx (NASDAQ:CDNA) reported third quarter 2026 Revenue of USD 139.4 million, up 39% from USD 100.1 million, and shares rose between about 20% and 22% on October 30, 2026.
- Testing Services revenue of USD 119.2 million rose 65%, or about 58% excluding prior period revenue, while Patient and Digital Solutions revenue rose 31% to USD 20.2 million.
- The company raised 2026 revenue guidance to USD 520 million to USD 530 million from USD 490 million to USD 500 million, and adjusted EBITDA guidance to USD 90 million to USD 100 million.
- GAAP Net Income was USD 19.3 million, adjusted EBITDA was USD 30.5 million, a 22% margin, and cash was USD 250.5 million at CareDx (NASDAQ:CDNA).
What CareDx Reported
CareDx (NASDAQ:CDNA) published third quarter results on October 29, 2026. Total revenue was USD 139.4 million, against about USD 122 million expected by analysts, according to published coverage. GAAP net income was USD 19.3 million, or USD 0.35 per diluted share, compared with USD 1.7 million a year earlier, and non-GAAP net income was USD 38.4 million. Test Volume was about 75,900, up 51% including contributions from NavDx. Operating Cash Flow was USD 12.7 million and free cash flow was USD 11.1 million. Chief Executive John Hanna described another strong quarter of solid execution with continued growth in transplant. Patient and Digital Solutions revenue was USD 20.2 million, up 31% from USD 15.4 million.
What Drives the Numbers
CareDx sells blood tests that monitor transplant recipients for signs of organ rejection, using donor derived cell free DNA to detect injury early. Published coverage says about USD 15 million of Testing Services revenue came from tests run in earlier periods, compared with USD 6 million a year earlier, so part of the beat will not repeat. Dividing Testing Services revenue by volume gives about USD 1,570 per test, simple arithmetic on two published numbers and not a company reported price. The raised outlook adds USD 30 million to the revenue midpoint, from USD 495 million to USD 525 million, and lifts the adjusted EBITDA midpoint from USD 72 million to USD 95 million.
Risks and What to Watch
Prior period revenue is one time, and operating cash flow of USD 12.7 million compares with about USD 37 million a year earlier, according to published coverage. Competition is a second risk: Natera, whose Prospera test competes with the CareDx kidney product, is due to report in the following week. A product launch planned for early 2027 must also go well for CareDx (NASDAQ:CDNA). Reimbursement rules, payer coverage and clinic adoption affect all transplant diagnostics, and the share price already reflects much of the good news. Investors should compare each number with the company filing and watch analyst price target changes after the jump, because a rise of 22% leaves less Margin for disappointment.
Where Things Stand
The company is CareDx (NASDAQ:CDNA), which soared because revenue grew 39%, profit and EBITDA rose sharply and full-year guidance was lifted well above prior ranges. The rally of about 20% to 22% reflects a clear beat and a bigger raise, though some revenue came from earlier periods and will not recur. The evidence is positive but not risk free, and the next catalysts are the competing results due next week and the early 2027 product launch.






Please wait processing your request...